CN101024082A - Compounded medicine for wholely preventing and treating cardio-cerebral blood vessel diseases and use thereof - Google Patents
Compounded medicine for wholely preventing and treating cardio-cerebral blood vessel diseases and use thereof Download PDFInfo
- Publication number
- CN101024082A CN101024082A CNA2007102004083A CN200710200408A CN101024082A CN 101024082 A CN101024082 A CN 101024082A CN A2007102004083 A CNA2007102004083 A CN A2007102004083A CN 200710200408 A CN200710200408 A CN 200710200408A CN 101024082 A CN101024082 A CN 101024082A
- Authority
- CN
- China
- Prior art keywords
- dosage
- release
- tablet
- agent
- estradiol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The present invention relates to a compound medicine for preventing and curing angiocardiopathy and cerebrovascular disease, belonging to the field of chemical medicine. It is characterized by that said compound medicine includes sexual hormones medicine, lipid-reducing medicine, hypotenser, hypoglycemic medicine and anticoagulant medicine. Said compound medicine can be made into various dosage forms. Besides, said compound medicine also can be used for curing the diseases of climacteric syndrome, osteoporosis, endometrial carcinoma, diabetes and metabolic syndrome, etc.
Description
Technical field
A kind of comprehensive prevention and treatment cardiovascular and cerebrovascular disease compound medicines.Belong to the chemicals field.
Background technology
In December, 2005, we have applied for the patent of invention of " a kind of prevention and treatment cardiovascular and cerebrovascular disease compound medicines and application thereof ", number of patent application: 2005102008329.After this, a large amount of new experimental evidence show that diabetes high-risk patient and impaired glucose tolerance patient can postpone the disease time of diabetes, the danger of reduction cardiovascular and cerebrovascular disease with pharmaceutical intervention or with specific hypoglycemic medicine.Therefore, on the basis of patent of invention in 2005, we have increased antidiabetic drug, make new compound medicines really accomplish comprehensive prevention and treatment cardiovascular and cerebrovascular disease.Now be expressed as follows:
1. cardiovascular and cerebrovascular disease is first killer who threatens human health.Sickness rate is the highest, and mortality rate is the highest, and still is growing trend.Therefore seek new ideal medicament and therapy, control and prophylactic development are current urgent task and social responsibility.2. the women is before menopause, and the cardiovascular and cerebrovascular disease sickness rate is very low, and its M ﹠ M is identical with the male after menopause.Thinking at present may be relevant with estrogen.3. a large amount of zoopery and clinical observations show: gonadal hormone especially estrogen can alleviate the damage of inflammatory factor to blood vessel, and protection damaged blood vessels and vascular endothelial cell suppress vascular smooth muscle cell curing, slows down the atheromatous plaque development; Can pass through nitric oxide approach blood vessel dilating, bring high blood pressure down; Can reduce low-density lipoprotein cholesterol (LDL_C), high density lipoprotein increasing cholesterol (HDL_C); Can reduce the former activator of fiber in the blood; Can increase myocardial contraction, improve the function and the survival rate of heart failure heart, the cardiac muscle of protection ischemia.Gonadal hormone can alleviate the symptom of female climacteric syndrome in addition, reduces osteoporosis, carcinoma of endometrium, senile dementia, the generation of diabetes etc.4. still gonadal hormone also has side effect, as the rising triglyceride, increases blood viscosity and thrombosis, especially under the situation that forms the blood vessel atheromatous plaque.Therefore especially estrogen should be in the early stage application of vascular injury to think gonadal hormone at present.In addition gonadal hormone especially estrogen can increase the generation of breast carcinoma.5. phytoestrogen conjugated estrogen hormone receptor optionally reduces estrogenic side effect, as the generation of breast carcinoma.6. at present a large amount of evidences show along with hypertension hyperlipidemia, the increase of hyperglycemia and metabolic syndrome sickness rate, the M ﹠ M of cardiovascular and cerebrovascular disease is the increase of corresponding proportion, hypertension, hyperlipidemia, hyperglycemia and metabolic syndrome are the bases of cardiovascular and cerebrovascular disease.Up-to-date data shows in the cardiovascular and cerebrovascular disease that 70% has sugared dysregulation, and the 2-3 that the dangerous male of cardiovascular and cerebrovascular disease is taken place in the diabetics is the normal person is doubly, the women be 3-5 doubly.The U.S. at first proposed the disease of endangering of waiting that diabetes are cardiovascular and cerebrovascular diseases in 2003, caused global concern and approval.Up-to-date test shows that diabetes high-risk patient and impaired glucose tolerance patient can postpone the disease time of diabetes with pharmaceutical intervention or with specific hypoglycemic medicine, reduce the danger of cardiovascular and cerebrovascular disease from now on.Therefore reduce the M ﹠ M of cardiovascular and cerebrovascular disease, must strictly control hypertension, hyperlipidemia, the development of hyperglycemia and metabolic syndrome, but single bring high blood pressure down or blood fat or blood glucose can not reach best result, have only comprehensive controlling blood pressure, blood fat, blood glucose is in perfect condition (blood pressure: 115/70mmHg; LDL_C:＜2.6mmol/l; HDL_C:＞1.0mmol/l; Blood glucose:＜6.0mmol/l) could reduce the generation of cardiovascular and cerebrovascular disease and reduce mortality rate significantly.7. same a large amount of zooperies and extensive clinical trial show fat-reducing medicament, antihypertensive drugs (beta-blocker, angiotensin transaminase inhibitor and angiotensin receptor blocker, calcium antagonist), antidiabetic drug, anticoagulant can alleviate the damage of inflammatory factor to blood vessel, suppress vascular smooth muscle cell curing, bring high blood pressure down, reduce low-density lipoprotein cholesterol (LDL_C), high density lipoprotein increasing cholesterol (HDL_C), slow down, stable and/or reverse blood vessel atheromatous plaque develops, and anticoagulant and thrombosis reduce the generation of cardiovascular and cerebrovascular vessel incident etc.But fat-reducing medicament, antihypertensive drugs (beta-blocker, angiotensin transaminase inhibitor and angiotensin receptor blocker, calcium antagonist), antidiabetic drug, anticoagulant also has side effect, as lipid-lowering statins infringement liver and smooth muscle, beta-blocker decreased heart rate, suppress myocardial contraction, calcium antagonist increases heart rate and sympathetic activation, and the use of angiotensin transaminase inhibitor and angiotensin receptor blocker is influenced by renal function, and anticoagulant causes bleeding etc.These side effect are most relevant with dosage.
Summary of the invention
1. the present invention is sex hormones, the blood fat reducing class, and the blood pressure lowering class, antidiabetic drug, anticoagulant class drug regimen becomes compound medicines; make them from varying level, the position, by way of, more comprehensively; to greatest extent, the protective effect of collaborative performance cardiovascular and cerebrovascular vessel reduces dosage simultaneously, reduces side effect to greatest extent and produces.This compound medicines can also suppress and/or alleviate side effects of pharmaceutical drugs mutually in addition, and share as beta-blocker and calcium antagonist can stable heart-rate, and anticoagulant can reduce gonadal hormone to influence of blood coagulation system etc.It is the desirable combination of comparatively optimizing.2. the medicine that does not still have the prevention cardiovascular and cerebrovascular disease of desirable (be effective in cure have no side effect again) at present.Because any single medicine all can't be competent at the task of the complicated cardiovascular and cerebrovascular disease of control.Be not that dosage is excessive, side effect increases, and is exactly that dosage is too small, and curative effect reduces, and is difficult to become ideal medicament.Just as the therapeuticcocktail of anti-retrovirals of treatment AIDS, have only drug combination could bring into play the effect of protection cardiovascular and cerebrovascular vessel to greatest extent, could on the basis that guarantees curative effect, reduce the generation of side effect to greatest extent simultaneously.This compound medicines has been concentrated the medicine of the most effective current protection cardiovascular and cerebrovascular vessel, optimum organization, and lowest dose level, minimal side effect is the medicine of current comparatively ideal control cardiovascular and cerebrovascular disease.3. this compound medicines is is suitably added and subtracted, to be suitable for different crowd on the basis of basic combination.As can be used for healthy population than low dosage, high-risk group's primary prevention, higher dosage can be used for cardiovascular and cerebrovascular disease patient's secondary prevention, prevent the further generation of cardiovascular and cerebrovascular vessel incident, increase estrogen, progestogen content can be used for the women in menopause, adopts phytoestrogen to can be used for adult male, regulates antihypertensive drugs content to adapt to different blood pressure crowds etc.
The specific embodiment
Embodiment 1: this compound medicines is by 17 β estradiol 0.5mg, medroxyprogesterone 0.3mg, and suffering is cut down its spit of fland 2.5mg, metoprolol 2.0mg, amlodipine 0.5mg, metformin 200mg, aspirin 75mg makes combination preparation, press oral formulations (conventional tablet, dispersible tablet, thin membrane coated tablet, Sublingual tablet, oral cavity disintegration tablet, enteric coatel tablets, slow releasing tablet, fast-release tablet, controlled release tablet, hard capsule, enteric coated capsule, slow releasing capsule etc.) preparation technology's program carries out.Be used for premature menopause phase women.Controlling blood pressure, blood fat, blood glucose is in perfect condition (blood pressure: 115/70mmHg; LDL_C:＜2.6mmol/l; HDL_C:＞1.0mmol/l; Blood glucose:＜6.0mmol/l).The control metabolic syndrome, the monitoring sex hormone level.
Embodiment 2: this compound medicines is by 17 β estradiol 0.5mg, medroxyprogesterone 0.3mg, and suffering is cut down its T5mg, metoprolol 2.0mg, amlodipine 0.5mg, acarbose 20mg, aspirin 100mg makes combination preparation, press oral formulations (conventional tablet, dispersible tablet, thin membrane coated tablet, Sublingual tablet, oral cavity disintegration tablet, enteric coatel tablets, slow releasing tablet, fast-release tablet, controlled release tablet, hard capsule, enteric coated capsule, slow releasing capsule etc.) preparation technology's program carries out.Be used for women in menopause in late period.Controlling blood pressure, blood fat, blood glucose is in perfect condition (blood pressure: 115/70mmHg; LDL_C:＜2.6mmol/l; HDL_C:＞1.0mmol/l; Blood glucose:＜6.0mmol/l).The control metabolic syndrome, the monitoring sex hormone level.
Embodiment 3: this compound medicines is by soybean isoflavone 300mg and/or 17 β estrogen 0.05mg, and suffering is cut down its spit of fland 2.5mg, metoprolol 2.0mg, amlodipine 0.5mg, pioglitazone 10mg, aspirin 40mg makes combination preparation, press oral formulations (conventional tablet, dispersible tablet, thin membrane coated tablet, Sublingual tablet, oral cavity disintegration tablet, enteric coatel tablets, slow releasing tablet, fast-release tablet, controlled release tablet, hard capsule, enteric coated capsule, slow releasing capsule etc.) preparation technology's program carries out.Be used for the adult male high-risk group.Controlling blood pressure, blood fat, blood glucose is in perfect condition (blood pressure: 115/70mmHg; LDL_C:＜2.6mmol/l; HDL_C:＞1.0mmol/l; Blood glucose:＜6.0mmol/l).The control metabolic syndrome, the monitoring sex hormone level.
Embodiment 4: this compound medicines is by soybean isoflavone 300mg and/or 17 β estrogen 0.05mg, lipanthyl 50mg, metoprolol 2.0mg, amlodipine 0.5mg, rosiglitazone 3mg, aspirin 40mg makes combination preparation, press oral formulations (conventional tablet, dispersible tablet, thin membrane coated tablet, Sublingual tablet, oral cavity disintegration tablet, enteric coatel tablets, slow releasing tablet, fast-release tablet, controlled release tablet, hard capsule, enteric coated capsule, slow releasing capsule etc.) preparation technology's program carries out.Be used for the high triglyceride crowd of adult male.Controlling blood pressure, blood fat, blood glucose is in perfect condition (blood pressure: 115/70mmHg; LDL_C:＜2.6mmol/l; HDL_C:＞1.0mmol/l; Blood glucose:＜6.0mmol/l).The control metabolic syndrome, the monitoring sex hormone level.
Embodiment 5: this compound medicines is by soybean isoflavone 300mg and/or 17 β estrogen 0.05mg, and suffering is cut down its spit of fland 20mg, metoprolol 12.5mg, amlodipine 2.5mg, gliclazide 30mg, aspirin 80mg makes combination preparation, press oral formulations (conventional tablet, dispersible tablet, thin membrane coated tablet, Sublingual tablet, oral cavity disintegration tablet, enteric coatel tablets, slow releasing tablet, fast-release tablet, controlled release tablet, hard capsule, enteric coated capsule, slow releasing capsule etc.) preparation technology's program carries out.Be used for the secondary prevention of cardiovascular and cerebrovascular disease.Controlling blood pressure, blood fat, blood glucose is in perfect condition (blood pressure: 115/70mmHg; LDL_C:＜2.6mmol/l; HDL_C:＞1.0mmol/l; Blood glucose:＜6.0mmol/l).The control metabolic syndrome, the monitoring sex hormone level.
The invention is not restricted to above-described embodiment.
Claims (10)
1. one kind is prevented and treatment cardiovascular and cerebrovascular disease compound medicines comprehensively, it is characterized by this compound medicines and comprises sex hormones, blood fat reducing class, blood pressure lowering class, antidiabetic drug, anticoagulant class medicine.And according to different crowd, on the basis of basic combination, press variety classes, dosage, ratio and dosage form, suitably plus-minus preparation.
2. compound medicines according to claim 1 is applied to climacteric women and adult male cardiovascular and cerebrovascular disease one, secondary prevention and treatment, and other diseases such as climacteric syndrome, osteoporosis, carcinoma of endometrium, senile dementia, diabetes, the control of diseases such as metabolism syndrome.
3. according to claim 1,2 described compound mediciness, wherein sex hormones comprises estrogen (estradiol, 17 β estradiol, estradiol benzoate, estradiol valerate, estradiol cypionate, conjugated estrogens, ethinylestradiol, nilestriol, the female alcohol of hexene, chlorotrianisene, estriol etc.), progestogen (progesterone, medroxyprogesterone, megestrol, chlormadinone, hydroxyprogesterone, norethindrone, norgestrel, gestrinone etc.), male's androgen (Testosterone Propionate, methyltestosterone, nandrolone phenylpropionate, danazol etc.), phytoestrogen (soybean isoflavone, daidzin etc.).Wherein estradiol dosage is from 0.1-50mg; 17 β estradiol dosage are from 0.1-50mg; Estradiol benzoate dosage is from 0.1-50mg; Estradiol valerate dosage is from 0.1-50mg; Estradiol cypionate dosage is from 0.1-50mg; Conjugated estrogens dosage is from 0.05-50mg; Ethinylestradiol dosage is from 0.1-1000ug; Nilestriol dosage is from 0.1-50mg; The female pure dosage of hexene is from 0.1-50mg; Chlorotrianisene dosage is from 0.1-50mg; Estriol dosage is from 0.1-100mg; Progesterone dosage is from 0.1-100mg; Medroxyprogesterone dosage is from 0.1-1000mg; Megestrol dosage is from 0.1-50mg; Chlormadinone dosage is from 0.01-50mg; Hydroxyprogesterone dosage is from 0.1-1000mg; Norethindrone dosage is from 0.05-100mg; Norgestrel dosage is from 0.1-100mg; Gestrinone dosage is from 0.1-50mg; Testosterone Propionate dosage is from 0.5-500mg; Methyltestosterone dosage is from 0.1-100mg; Nandrolone phenylpropionate dosage is from 0.1-200mg; Danazol dosage is from 1-1000mg; Soybean isoflavone dosage is from 0.1-1000mg; Daidzin dosage is from 0.1-1000mg etc.And according to different crowd, by various dose, ratio, independent and/or co-formulated.
4. according to claim 1,2 described compound mediciness, wherein blood fat reducing class comprises statins (lovastatin, simvastatin, pravastatin, atorvastatin, fluvastatin, simvastatin etc.), the special class medicine of shellfish (fenofibrate, gemfibrozil, bezafibrate, chlorine Bei Te, acipimox, probucol, lipanthyl etc.), plant class (Monas cuspurpureus Went etc.).Wherein lovastatin dosage is from 0.1-200mg; Simvastatin is from 0.1-200mg; Pravastatin dosage is from 0.1-200mg; Atorvastatin dosage is from 0.1-200mg; Fluvastatin dosage is from 0.1-200mg; Simvastatin dosage is from 0.1-200mg; Fenofibrate dosage is from 1-2000mg; Gemfibrozil dosage is from 1-2000mg; Bezafibrate dosage is from 1-2000mg; The special dosage of chlorine shellfish is from 1-2000mg; Acipimox dosage is from 1-2000mg; Probucol dosage is from 1-2000mg; Lipanthyl dosage is from 1-500mg; Monas cuspurpureus Went dosage is from 1-3000mg.And according to different crowd, by various dose, ratio, independent and/or co-formulated.
5. according to claim 1,2 described compound mediciness, wherein blood pressure lowering class comprises beta-blocker (metoprolol, bisoprolol, atenolol, Propranolol, carvedilol, timolol, labetalol, dilevalol, celiprolol, amosulalol, Almarl etc.), calcium antagonist (nifedipine, amlodipine, diltiazem, felodipine, Isradipine, nicardipine, the Mi Baifu Horizon, verapamil, nisoldipine, lacidipine etc.), angiotensin receptor blocker (losartan, valsartan, irbesartan, Candesartan, eprosartan, Tasosartan, telmisartan etc.).Angiotensin transaminase inhibitor (captopril, enalapril, benazepril, lisinopril, ramipril, fosinopril, cilazapril, perindopril, quinapril, trandolapril, delapril, Imidapril etc.).Wherein metoprolol dosage is from 0.1-500mg; Bisoprolol dosage is from 0.1-100mg; Atenolol dosage is from 0.1-100mg; Propranolol dosage is from 0.1-100mg; Carvedilol dosage is from 0.1-100mg; Timolol dosage is from 0.1-100mg; Labetalol dosage is from 0.1-100mg; Dilevalol dosage is from 0.1-100mg; Celiprolol dosage is from 0.1-100mg; Amosulalol dosage is from 0.1-100mg; Almarl dosage is from 0.1-100mg; Nifedipine dosage is from 0.1-200mg; Amlodipine dosage is from 0.1-100mg; Diltiazem dosage is from 0.1-200mg; Felodipine dosage is from 0.1-100mg; Isradipine dosage is from 0.1-100mg; Nitrendipine dosage is from 0.1-200mg; Nicardipine dosage is from 0.1-200mg; Nisoldipine dosage is from 0.1-200mg; Mi Baifu Horizon dosage is from 0.1-100mg; Verapamil dosage is from 0.1-200mg; Lacidipine dosage is from 0.1-100mg; Captopril dosage is from 0.1-200mg; Enalapril dosage is from 0.1-100mg; Benazepril dosage is from 0.1-100mg; Lisinopril dosage is from 0.1-100mg; Ramipril dosage is from 0.1-100mg; Fosinopril dosage is from 0.1-100mg; Cilazapril dosage is from 0.1-100mg; Perindopril dosage is from 0.1-100mg; Quinapril dosage is from 0.1-100mg; Trandolapril dosage is from 0.1-100mg; Delapril dosage is from 0.1-100mg; Imidapril dosage is from 0.1-100mg etc.And according to different crowd, by various dose, ratio, independent and/or co-formulated.
6. according to claim 1,2 described compound mediciness, wherein antidiabetic drug comprises sulfonylurea (gliclazide, glimepiride, glipizide, gliquidone, glibenclamide, acetohexamide, tolbutamide), meglitinide (repaglinide, Nateglinide), alpha-glucosidase inhibitor (acarbose, miglitol, voglibose), biguanides (metformin), glitazone (pioglitazone, rosiglitazone).Wherein gliclazide dosage is from 5-200mg, glimepiride dosage is from 0.2-6mg, glipizide dosage is from 0.5-30mg, gliquidone dosage is from 3-120mg, glibenclamide dosage is from 0.3-15mg, acetohexamide dosage is from 100-1500mg, tolbutamide dosage is from 50-3000mg, and repaglinide dosage is from 0.1-16mg, and Nateglinide dosage is from 20-1000mg, acarbose dosage is from 5-200mg, miglitol dosage is from 5-100mg, and voglibose dosage is from 0.04-3mg, and metformin dosage is from 50-3000mg, pioglitazone dosage is from 3-30mg, and rosiglitazone dosage is from 1-8mg etc.And according to different crowd, by various dose, ratio, independent and/or co-formulated.
7. according to claim 1,2 described compound mediciness, wherein anticoagulant comprises aspirin, warfarin etc.Wherein aspirin dosage is from 10-500mg.Warfarin is from 0.1-10mg.And according to different crowd, by various dose, ratio, independent and/or co-formulated.
8. according to claim 1,2 described compound mediciness is characterized in that: get principal agent and filler, disintegrating agent, surfactant, cosolvent, binding agent mixes, and guiding humid medium system soft material is granulated, dry, granulate adds lubricant, tabletting, make oral ordinary tablet, should oral ordinary tablet bag film-coat or enteric coating can further make Film coated tablets or enteric coatel tablets; Get principal agent and filler, binding agent mixes, and guiding humid medium system soft material is granulated, drying, and granulate adds correctives, lubricant, tabletting is made Sublingual tablet.Get principal agent and filler, disintegrating agent helps and collapses agent, surfactant, and surfactant mixes, and adds correctives, lubricant, tabletting is made dispersible tablet, oral cavity disintegration tablet; Get principal agent and slow release and/or rapid release and/or controlled-release material and mix, guiding humid medium system soft material is granulated, drying, and granulate adds lubricant, and tabletting is made slow releasing tablet, fast-release tablet, controlled release tablet.
9. according to claim 1,2 described compound mediciness is characterized in that: get principal agent and filler, disintegrating agent, surfactant, cosolvent, binding agent mixes, guiding humid medium system soft material, granulate, be filled into Capsules, make hard capsule, the capsule of preparation is handled with the coating enteric material, can further be made enteric coated capsule; Get principal agent and slow release and/or rapid release and/or controlled-release material and make one or more slow release and/or rapid release and/or controlled release piller, fill separately or mixing back filling Capsules, make slow release and/or quick-release capsules or controlled release capsule.
10. according to claim 1,2 described polypharmaceutic adjuvants: filler is arranged, binding agent, surfactant, wetting agent, wetting agent, disintegrating agent, help and collapse agent, suspending agent, fluidizer, lubricant, correctives, adsorbent, suspensoid, coating material, coating material, slow-release material, rapid release material, controlled-release material etc.Wherein filler includes but not limited to lactose, sucrose, glucose, mannitol, sorbitol, calcium sulfate, calcium gluconate, calcium hydrogen phosphate, calcium carbonate, starch, carboxymethyl starch, pregelatinized Starch, microcrystalline Cellulose etc.Binding agent includes but not limited to starch, pregelatinized Starch, gelatin, dextrin, maltodextrin, sucrose, arabic gum, polyvinylpyrrolidone, various viscosity methylcellulose, low viscosity carboxymethyl cellulose, various viscosity ethyl celluloses, various viscosity polyvinyl alcohol, polyethylene glycol 6000, the following hydroxypropyl emthylcellulose of 5MPAS etc.Disintegrating agent includes but not limited to starch, pregelatinized Starch, microcrystalline Cellulose, alginic acid, pure lignocellulose, carboxymethyl starch sodium, guar gum, crospolyvinylpyrrolidone, ion exchange resin, methylcellulose, sodium carboxymethyl cellulose etc.; Lubricant includes but not limited to magnesium stearate, calcium stearate, zinc stearate, Pulvis Talci, glyceryl monostearate, polyethylene glycol 6000, Polyethylene Glycol 8000, sodium benzoate, adipic acid, fumaric acid, boric acid, sodium chloride, triacetyl glycerine, polyoxyethylene monostearate, single Laurel sucrose acid ester, sodium chloride, sodium laurylsulfate, magnesium laurylsulfate etc.; Surfactant comprises but is not limited to sodium lauryl sulphate, smelting Luo Shamu, Tween 80, bromination hexadecane trimethylamine, sodium laurylsulfate, stearyl alcohol semi-annular jade pendant acid sodium, polyoxyethylene high fatty alcohol, sucrose fat, sorbitol fatty ester, soybean phospholipid etc.; Correctives includes but not limited to steviosin, fructose, glucose, high fructose syrup, Mel, aspartame, protein sugar, xylitol, mannitol essence, Fructus Citri tangerinae essence, Herba Menthae essence, Fructus Foeniculi, vanillin, Fructus Citri Limoniae essence, cherry essence, rose essence etc.Coating material includes but not limited to cellulose and derivatives class thereof, crylic acid resin, ethene polymers etc.Coating material includes but not limited to gelatin, arabic gum, carboxymethyl cellulose, polyvinyl alcohol, polyacrylic acid, hydroxyethyl-cellulose, polylactic acid, ethyl cellulose, polyethylene, polyamide, stearic acid, celluloid, tristerin, Lac, Cellulose Acetate Phthalate; Slow release, rapid release, controlled release matrix material include but not limited to that babassu is cured, castor oil hydrogenated, Semen Ricini is cured, and hydrogenated castor is cured, hydrogenated soya phosphatide, Lac, gelatin, sodium alginate, chitosan, amylopectin, agar, carrageenin, guar gum, cellulose derivative, crylic acid resin, polyethylene kind, macromolecular material etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007102004083A CN101024082A (en) | 2007-04-06 | 2007-04-06 | Compounded medicine for wholely preventing and treating cardio-cerebral blood vessel diseases and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007102004083A CN101024082A (en) | 2007-04-06 | 2007-04-06 | Compounded medicine for wholely preventing and treating cardio-cerebral blood vessel diseases and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101024082A true CN101024082A (en) | 2007-08-29 |
Family
ID=38742925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007102004083A Pending CN101024082A (en) | 2007-04-06 | 2007-04-06 | Compounded medicine for wholely preventing and treating cardio-cerebral blood vessel diseases and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101024082A (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101862309A (en) * | 2009-04-17 | 2010-10-20 | 北京以岭生物工程有限公司 | Glipizide sustained-release capsule and preparation method thereof |
| CN101869708A (en) * | 2009-04-24 | 2010-10-27 | 北京奥萨医药研究中心有限公司 | Medicament composition containing calcium channel blockers and biguanide antidiabetic medicine and application thereof |
| JP2011505344A (en) * | 2007-12-03 | 2011-02-24 | ディーエスエム アイピー アセッツ ビー．ブイ． | Novel nutritional food composition containing stevia extract or stevia extract constituent and use thereof |
| US9233113B2 (en) | 2009-06-22 | 2016-01-12 | Ampio Pharmaceuticals, Inc. | Method for treatment of diseases |
| CN105476995A (en) * | 2015-12-23 | 2016-04-13 | 青岛海之源智能技术有限公司 | Metformin-acipimox compound sustained-release capsule and preparing method |
| US9351979B2 (en) | 2012-12-19 | 2016-05-31 | Ampio Pharmaceuticals, Inc. | Methods of treatment of diseases |
| CN106390094A (en) * | 2016-11-11 | 2017-02-15 | 上海雅本化学有限公司 | Trandolapril-containing pharmaceutical composition and preparation method thereof |
| CN106511633A (en) * | 2017-01-24 | 2017-03-22 | 何远知 | Oral slow-release tablet of antihypertensive drug and preparation method thereof |
| CN107184952A (en) * | 2017-06-13 | 2017-09-22 | 江苏黄河药业股份有限公司 | A kind of lisinopril compound preparation and preparation method thereof |
| CN109069438A (en) * | 2016-04-20 | 2018-12-21 | 法国施维雅药厂 | Pharmaceutical composition comprising beta-blocker, converting enzyme inhibitor and antihypertensive or NSAID |
| JP2022136301A (en) * | 2022-04-28 | 2022-09-15 | 小林製薬株式会社 | Solid preparation |
-
2007
- 2007-04-06 CN CNA2007102004083A patent/CN101024082A/en active Pending
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011505344A (en) * | 2007-12-03 | 2011-02-24 | ディーエスエム アイピー アセッツ ビー．ブイ． | Novel nutritional food composition containing stevia extract or stevia extract constituent and use thereof |
| CN101862309A (en) * | 2009-04-17 | 2010-10-20 | 北京以岭生物工程有限公司 | Glipizide sustained-release capsule and preparation method thereof |
| CN101862309B (en) * | 2009-04-17 | 2015-10-21 | 北京以岭生物工程技术有限公司 | Glipizide sustained-release capsule and preparation method thereof |
| CN101869708A (en) * | 2009-04-24 | 2010-10-27 | 北京奥萨医药研究中心有限公司 | Medicament composition containing calcium channel blockers and biguanide antidiabetic medicine and application thereof |
| US9233113B2 (en) | 2009-06-22 | 2016-01-12 | Ampio Pharmaceuticals, Inc. | Method for treatment of diseases |
| US9987292B2 (en) | 2009-06-22 | 2018-06-05 | Ampio Pharmaceuticals, Inc. | Method for treatment of diseases |
| US9351979B2 (en) | 2012-12-19 | 2016-05-31 | Ampio Pharmaceuticals, Inc. | Methods of treatment of diseases |
| US10058562B2 (en) | 2012-12-19 | 2018-08-28 | Ampio Pharmaceuticals, Inc. | Methods of treatment of diseases |
| CN105476995A (en) * | 2015-12-23 | 2016-04-13 | 青岛海之源智能技术有限公司 | Metformin-acipimox compound sustained-release capsule and preparing method |
| CN109069438A (en) * | 2016-04-20 | 2018-12-21 | 法国施维雅药厂 | Pharmaceutical composition comprising beta-blocker, converting enzyme inhibitor and antihypertensive or NSAID |
| CN106390094A (en) * | 2016-11-11 | 2017-02-15 | 上海雅本化学有限公司 | Trandolapril-containing pharmaceutical composition and preparation method thereof |
| CN106511633A (en) * | 2017-01-24 | 2017-03-22 | 何远知 | Oral slow-release tablet of antihypertensive drug and preparation method thereof |
| CN107184952A (en) * | 2017-06-13 | 2017-09-22 | 江苏黄河药业股份有限公司 | A kind of lisinopril compound preparation and preparation method thereof |
| JP2022136301A (en) * | 2022-04-28 | 2022-09-15 | 小林製薬株式会社 | Solid preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101024082A (en) | Compounded medicine for wholely preventing and treating cardio-cerebral blood vessel diseases and use thereof | |
| KR101209319B1 (en) | Pharmaceutical Formulation comprising Angiotensin-Ⅱ-receptor blockers | |
| AU719170B2 (en) | Pharmaceutical compressed tablet characterized by a high increase in volume by contact with biological fluids | |
| US20130310455A1 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
| US20150250746A1 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
| US10912785B2 (en) | Composition and medical device comprising acetylsalicylic acid for the treatment of human papilloma virus skin infections | |
| CN101647805B (en) | Glucosamine chewable tablet used for relieving and preventing osteoarthritis and preparation method thereof | |
| ES2207334T3 (en) | PHARMACEUTICAL COMPOSITION OF CONTROLLED LIBERATION, WITH TILIDINE MESILATE AS ACTIVE PRINCIPLE. | |
| CN101822672A (en) | Compound with metformin and repaglinide, preparation method thereof and application thereof | |
| EP0749308A1 (en) | Film coated tablet of paracetamol and domperidone | |
| CN102125531A (en) | Nifedipine sustained-release tablet | |
| CN1824312A (en) | Compound medicine for preventing and treating cardio vascular cerebral vascular disease and its application | |
| NZ539192A (en) | Sustained release composition for oral administration of drugs | |
| KR102055859B1 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
| CN101015519B (en) | Loratadine oral compound medication composition | |
| SK284728B6 (en) | A pharmaceutical composition comprising ibuprofen and domperidone for the treatment of migraine | |
| AU9340198A (en) | Novel composition | |
| CN100336502C (en) | Yunnan Manyleaf paris Rhizome extract ora disintegration tablet and its preparing process | |
| CN1861066A (en) | Compounding oral prepn. contg. paracetamol and methionine | |
| CA2746531A1 (en) | Non-steroidal anti-inflammatory drug dosage form | |
| KR20090047310A (en) | Multilayered tablet containing dexibuprofen | |
| CN1430956A (en) | Medicine for treating intestinal tract disease | |
| CN1191830C (en) | Orally disintegrating Nifedipine prepn and its recipe | |
| CA2771831C (en) | Oral pharmaceutical composition comprising diclofenac | |
| CN104188930A (en) | Acemetacin three-layer controlled release tablets and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |